INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

Abstract Introduction Diffuse midline gliomas (DMG) are universally lethal central nervous system tumors that carry almost unanimously the clonal driver mutation histone-3 K27M (H3K27M). The single amino acid substitution of lysine to methionine harbors a neoantigen that is presented in tumor tissue...

Full description

Bibliographic Details
Main Authors: Niklas Grassl, Katharina Sahm, Heike Süße, Isabel Poschke, Lukas Bunse, Theresa Bunse, Tamara Boschert, Iris Mildenberger, Anne-Kathleen Rupp, Max Philipp Ewinger, Lisa-Marie Lanz, Monika Denk, Ghazaleh Tabatabai, Michael W. Ronellenfitsch, Ulrich Herrlinger, Martin Glas, Dietmar Krex, Peter Vajkoczy, Antje Wick, Inga Harting, Felix Sahm, Andreas von Deimling, Martin Bendszus, Wolfgang Wick, Michael Platten
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Neurological Research and Practice
Subjects:
Glioma
Central nervous system tumor
Diffuse midline glioma
T cell
Vaccine
Antigen
Online Access:https://doi.org/10.1186/s42466-023-00282-4

Internet

https://doi.org/10.1186/s42466-023-00282-4

Similar Items